NEW YORK (GenomeWeb) – Rennova Health subsidiary Medytox Diagnostics has partnered with Genomas to launch a series of pharmacogenetics tests to determine a patient's capacity to metabolize certain drugs and potentially tailor treatments to an individual's specific genetic makeup.

The tests they will be performed via a US Food and Drug Administration-approved in vitro diagnostic (IVD) genotyping kit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.